Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von StockNews.com 

Bio-Techne Corp. diskutieren

Bio-Techne Corp.

WKN: A12ENG / Symbol: TECH / Name: Bio-Techne / Aktie / Ausrüstung & Versorgung / Mid Cap /

66,50 €
0,76 %

Bio-Techne Co. (NASDAQ: TECH) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for TECH provided by MarketBeat

Einschätzung Buy
Rendite (%) -8,08 %
Kursziel 110,44
Veränderung
Endet am 18.08.24

Bio-Techne Co. (NASDAQ: TECH) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $120.00 price target on the stock.
Ratings data for TECH provided by MarketBeat

Bio-Techne Co. (NASDAQ: TECH) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.
Ratings data for TECH provided by MarketBeat

Bio-Techne Co. (NASDAQ: TECH) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for TECH provided by MarketBeat

Einschätzung Buy
Rendite (%) 32,13 %
Kursziel 75,94
Veränderung
Endet am 01.11.24

Bio-Techne Co. (NASDAQ: TECH) had its price target lowered by analysts at KeyCorp from $115.00 to $80.00. They now have an "overweight" rating on the stock.
Ratings data for TECH provided by MarketBeat

Einschätzung Buy
Rendite (%) 33,45 %
Kursziel 75,66
Veränderung
Endet am 01.11.24

Bio-Techne Co. (NASDAQ: TECH) had its price target lowered by analysts at Citigroup Inc. from $100.00 to $80.00. They now have a "buy" rating on the stock.
Ratings data for TECH provided by MarketBeat

Einschätzung Buy
Rendite (%) 20,59 %
Kursziel 60,63
Veränderung
Endet am 03.11.24

Bio-Techne Co. (NASDAQ: TECH) had its price target lowered by analysts at Stifel Nicolaus from $104.00 to $65.00. They now have a "buy" rating on the stock.
Ratings data for TECH provided by MarketBeat

Einschätzung Buy
Rendite (%) 5,04 %
Kursziel 74,12
Veränderung
Endet am 07.12.24

Bio-Techne Co. (NASDAQ: TECH) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $80.00 price target on the stock.
Ratings data for TECH provided by MarketBeat

Einschätzung Buy
Rendite (%) 8,37 %
Kursziel 80,65
Veränderung
Endet am 02.02.25

Bio-Techne Co. (NASDAQ: TECH) had its price target lowered by analysts at Stephens from $92.00 to $87.00. They now have an "overweight" rating on the stock.
Ratings data for TECH provided by MarketBeat

Einschätzung Buy
Rendite (%) -4,89 %
Kursziel 75,67
Veränderung
Endet am 02.05.25

Bio-Techne Co. (NASDAQ: TECH) had its price target raised by analysts at Robert W. Baird from $73.00 to $81.00. They now have an "outperform" rating on the stock.
Ratings data for TECH provided by MarketBeat

Einschätzung Buy
Rendite (%) -5,57 %
Kursziel 88,85
Veränderung
Endet am 02.05.25

Bio-Techne Co. (NASDAQ: TECH) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $95.00 price target on the stock.
Ratings data for TECH provided by MarketBeat